Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: 3 - The Untold Story

Top executives explain how they achieve ESG goals amid backlash

How should companies reframe ESG initiatives amid controversy? These executives offer their strategies.

I asked the world’s top CEOs if they’re taking diversity seriously. Here’s why their answers could change your life

I asked the world’s top CEOs if they’re taking diversity seriously. Here’s why their answers could change your life

Corporate culture has entered the fourth phase in its history: the integration of purpose and profit, writes Robert Reiss.

Here's How Much You Would Have Made Owning Zoetis Stock In The Last 5 Years

Here's How Much You Would Have Made Owning Zoetis Stock In The Last 5 Years

Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 13.08% on an annualized basis producing an average annual return of 22.15%. Currently, Zoetis has a market capitalization of $79.88 billion.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Explained | Ancovax - India’s first COVID-19 vaccine for animals

The Centre has launched a COVID-19 vaccine for animals such as dogs, lions, leopards, mice and rabbits.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,500 Today

Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 11.89% on an annualized basis producing an average annual return of 20.56%. Currently, Zoetis has a market capitalization of $75.58 billion.

Here's How Much You Would Have Made Owning Zoetis Stock In The Last 5 Years

Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 10.79% on an annualized basis producing an average annual return of 21.83%. Currently, Zoetis has a market capitalization of $79.47 billion.

Zoetis vs. IDEXX Laboratories: Which Animal-Health Services Stock is a Better Buy?

Rising pet ownership and an increasing focus on healthy livestock have boosted the demand for animal healthcare solutions. Therefore, animal healthcare service providers Zoetis (ZTS) and IDEXX Laboratories (IDXX) should benefit. But the stocks of which of these two companies is a better buy now? Read on to learn our…

inkl

Read news from The Economist, FT, and more,
with one subscription

Zoetis Earnings Perspective: Return On Invested Capital

Zoetis Earnings Perspective: Return On Invested Capital

According to Benzinga Pro, during Q1, Zoetis (NYSE:ZTS) earned $594.00 million, a 43.83% increase from the preceding quarter. Zoetis also posted a total of $1.99 billion in sales, a 0.97% increase since Q4.

Zoetis: Q1 Earnings Insights

Zoetis: Q1 Earnings Insights

Zoetis (NYSE:ZTS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Zoetis beat estimated earnings by 7.32%, reporting an EPS of $1.32 versus an estimate of $1.23.

Why Stephanie Link Is Watching Starbucks And This Stock Down Nearly 30% YTD

Why Stephanie Link Is Watching Starbucks And This Stock Down Nearly 30% YTD

Hightower Advisors' Stephanie Link believes we are still in the midst of a bull market. Accordingly, she has identified a couple of stocks well off their highs that she would like to buy on any further weakness.

Zoetis's Return On Capital Employed Insights

Zoetis's Return On Capital Employed Insights

Pulled from Benzinga Pro data, Zoetis (NYSE:ZTS) posted Q4 earnings of $413.00 million, an increase from Q3 of 25.18%. Sales dropped to $1.97 billion, a 1.16% decrease between quarters.

Zoetis Q4 Sales Cushioned By Higher Companion Animal Product Sales, Issues FY22 Outlook

Zoetis Q4 Sales Cushioned By Higher Companion Animal Product Sales, Issues FY22 Outlook

Zoetis Inc (NYSE: ZTS) has reported Q4 FY21 revenue of $2 b

Zoetis: Q4 Earnings Insights

Zoetis: Q4 Earnings Insights

Zoetis (NYSE:ZTS) reported its Q4 earnings results on Tuesday, February 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

1 2 3

People

Narendra Singh Tomar

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Intel Corporation

Walgreens Boots Alliance

IDEXX Laboratories

Hightower Advisors

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play